Corrigendum: The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China
Year: 2024
Type: erratum
Abstract: In the published article, there was an error. [There was a clerical error in writing].A correction has been made to [Abstract], [Findings], [Paragraph One]. This sentence previously stated:“[The PC strategies are considered more cost-effective than T-DXd when the WTP threshold is set at $36,058.06 per QALY.]”The corrected sentence appears below:“[The PC strategies are considered more cost-effective than T-DM1 when the WTP threshold is set at $36,058.06 per QALY.]”The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Source: Frontiers in Pharmacology
Authors: Lu Li, Shilei Yang, Fengqi Fang, Li Tian, Ying He, Jia Li, Yanwei Chen, Deshi Dong
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: gold
Estimated APC paid: $3,295
OpenAlex ID: W4404218188